Accolade, Inc.

NasdaqGS:ACCD Stock Report

Market Cap: US$285.1m

Accolade Valuation

Is ACCD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACCD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACCD ($3.54) is trading below our estimate of fair value ($49.46)

Significantly Below Fair Value: ACCD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACCD?

Key metric: As ACCD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ACCD. This is calculated by dividing ACCD's market cap by their current revenue.
What is ACCD's PS Ratio?
PS Ratio0.6x
SalesUS$441.03m
Market CapUS$285.10m

Price to Sales Ratio vs Peers

How does ACCD's PS Ratio compare to its peers?

The above table shows the PS ratio for ACCD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
AIRS AirSculpt Technologies
1.7x9.3%US$323.0m
VMD Viemed Healthcare
1.5x12.9%US$317.7m
AONC American Oncology Network
0.08xn/aUS$205.6m
BDSX Biodesix
3.3x19.7%US$215.3m
ACCD Accolade
0.6x11.4%US$285.1m

Price-To-Sales vs Peers: ACCD is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does ACCD's PS Ratio compare vs other companies in the US Healthcare Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$73.20b
CVS CVS Health
0.2x4.5%US$55.99b
COR Cencora
0.1x6.4%US$43.86b
CNC Centene
0.2x5.5%US$30.59b
ACCD 0.6xIndustry Avg. 1.0xNo. of Companies27PS012345+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ACCD is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is ACCD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACCD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: ACCD is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACCD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.54
US$7.17
+102.7%
19.1%US$9.50US$5.00n/a12
Dec ’25US$3.86
US$7.26
+88.0%
17.3%US$9.50US$5.34n/a12
Nov ’25US$3.20
US$7.08
+121.4%
19.1%US$9.50US$5.00n/a13
Oct ’25US$3.75
US$8.29
+121.0%
25.7%US$13.00US$5.34n/a15
Sep ’25US$4.34
US$8.08
+86.3%
27.4%US$13.00US$5.00n/a16
Aug ’25US$3.88
US$8.27
+113.1%
26.2%US$13.00US$5.00n/a15
Jul ’25US$3.54
US$8.27
+133.5%
26.2%US$13.00US$5.00n/a15
Jun ’25US$7.08
US$13.07
+84.6%
15.4%US$16.00US$10.00n/a15
May ’25US$7.36
US$13.33
+81.2%
16.8%US$17.00US$10.00n/a15
Apr ’25US$10.13
US$15.07
+48.7%
12.0%US$18.00US$12.00n/a15
Mar ’25US$9.96
US$15.07
+51.3%
12.0%US$18.00US$12.00n/a15
Feb ’25US$11.73
US$15.00
+27.9%
12.3%US$18.00US$12.00n/a14
Jan ’25US$12.01
US$14.77
+23.0%
15.3%US$17.00US$10.00n/a13
Dec ’24US$9.06
US$14.85
+63.9%
14.9%US$17.00US$10.00US$3.8613
Nov ’24US$6.69
US$15.08
+125.4%
13.6%US$17.00US$10.00US$3.2013
Oct ’24US$10.58
US$16.50
+56.0%
10.5%US$19.00US$14.00US$3.7513
Sep ’24US$13.71
US$16.23
+18.4%
10.8%US$19.00US$14.00US$4.3415
Aug ’24US$14.98
US$16.23
+8.4%
10.8%US$19.00US$14.00US$3.8815
Jul ’24US$13.47
US$16.23
+20.5%
10.8%US$19.00US$14.00US$3.5415
Jun ’24US$12.48
US$15.53
+24.5%
10.9%US$18.00US$13.00US$7.0815
May ’24US$13.02
US$15.53
+19.3%
10.9%US$18.00US$13.00US$7.3615
Apr ’24US$14.38
US$13.75
-4.4%
13.9%US$17.00US$10.00US$10.1314
Mar ’24US$12.39
US$13.19
+6.5%
12.0%US$15.00US$10.00US$9.9613
Feb ’24US$11.84
US$13.04
+10.1%
12.3%US$15.00US$10.00US$11.7313
Jan ’24US$7.79
US$13.93
+78.8%
14.2%US$17.00US$10.00US$12.0114
Dec ’23US$8.97
US$13.93
+55.3%
14.2%US$17.00US$10.00US$9.0614

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 16:13
End of Day Share Price 2024/12/27 00:00
Earnings2024/08/31
Annual Earnings2024/02/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Accolade, Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew GillmorBaird
Zhilin LongBerenberg
Allen LutzBofA Global Research